PREDNICARBATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDNICARBATE (PREDNICARBATE).
Prednicarbate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes.
| Metabolism | Prednicarbate is hydrolyzed in the skin to its active metabolite, prednisolone, which is further metabolized via hepatic pathways, primarily by CYP3A4. |
| Excretion | Primarily renal (<2% unchanged) and fecal (biliary excretion of metabolites) |
| Half-life | Terminal elimination half-life: approximately 1-2 hours; clinical context: short half-life supports topical use with minimal systemic accumulation |
| Protein binding | ~85% bound to albumin and corticosteroid-binding globulin |
| Volume of Distribution | Approximately 0.3 L/kg, indicating distribution primarily into extracellular fluid |
| Bioavailability | Topical: low systemic bioavailability (<1% through intact skin); oral: not applicable; no parenteral formulation |
| Onset of Action | Topical: within hours; clinical improvement typically observed within 3-7 days |
| Duration of Action | Duration of clinical effect: up to 12 hours; applied twice daily for dermatologic conditions |
Topical: apply sparingly to affected area twice daily; maximum 50 g per week.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for hepatic impairment; systemic absorption is minimal. |
| Pediatric use | Children >1 year: apply sparingly to affected area twice daily; limit treatment to 2 weeks; avoid occlusive dressings. Use lowest potency and shortest duration. |
| Geriatric use | Use with caution due to thinner skin; apply sparingly for shortest duration necessary; avoid large body surface area use. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREDNICARBATE (PREDNICARBATE).
| Breastfeeding | Excretion into breast milk is unknown. Due to low systemic absorption after topical application, transfer is likely negligible. Use caution with large areas or prolonged treatment. No M/P ratio available. |
| Teratogenic Risk | Prednicarbate is a topical corticosteroid. Systemic absorption is minimal, but first trimester use may slightly increase risk of oral clefts (OR 1.3-1.7). Second and third trimester use: no increased risk of major malformations, but possible intrauterine growth restriction with prolonged high-dose use. Limited data; overall risk low. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to prednicarbate or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic skin infections","Perioral dermatitis","Rosacea","Acne vulgaris"]
| Precautions | ["Systemic absorption may occur with prolonged use, especially on large surface areas, under occlusion, or on broken skin, leading to HPA axis suppression.","Local adverse reactions include skin atrophy, telangiectasias, striae, and contact dermatitis.","Use with caution in patients with skin infections, as corticosteroids may mask or worsen infections.","Pediatric patients may be more susceptible to systemic toxicity due to higher skin-to-body mass ratio."] |
Loading safety data…
| Fetal Monitoring |
| Monitor fetal growth with serial ultrasound if prolonged use over large body surface area; assess for signs of maternal adrenal suppression (rare with typical use). |
| Fertility Effects | No known effect on fertility in humans. Animal studies not reported with prednicarbate; topical corticosteroids generally show no effect on fertility. |